Ensysce Biosciences posted a Q2 net loss of $2.6 million, widening from a $1.7 million loss a year earlier.
Cash and cash equivalents fell to $676,704 at June 30 from $4.3 million at Dec. 31, 2025.
R&D expense rose to $2.5 million from $1.9 million, driven by higher external costs tied to PF614 clinical activity.
Federal grant funding slipped to $1.2 million from $1.4 million on timing of MPAR grant-eligible research.
Ensysce completed the Cy Biopharma acquisition, adding orphan-designated CRPS candidate CY200; financings provided about $31 million net cash, extending runway into late 2027.
ENSC•
